Congress Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,195
| Closed | -$343K | – | 387 |
|
|
2025
Q3 | $343K | Buy |
+2,195
| New | +$349K | ﹤0.01% | 372 |
|
|
2025
Q2 | – | Sell |
-2,879
| Closed | -$433K | – | 387 |
|
|
2025
Q1 | $433K | Sell |
2,879
-1,482
| -34% | -$248K | ﹤0.01% | 331 |
|
|
2024
Q4 | $805K | Sell |
4,361
-429,504
| -99% | -$82.7M | 0.01% | 327 |
|
|
2024
Q3 | $85.5M | Sell |
433,865
-9,239
| -2% | -$1.92M | 0.58% | 77 |
|
|
2024
Q2 | $91.5M | Sell |
443,104
-10,288
| -2% | -$2.33M | 0.66% | 70 |
|
|
2024
Q1 | $123M | Sell |
453,392
-11,866
| -3% | -$2.83M | 0.88% | 47 |
|
|
2023
Q4 | $110M | Sell |
465,258
-3,294
| -0.7% | -$648K | 0.87% | 49 |
|
|
2023
Q3 | $91.8M | Buy |
468,552
+1,446
| +0.3% | +$297K | 0.81% | 59 |
|
|
2023
Q2 | $98.2M | Buy |
467,106
+486
| +0.1% | +$96.7K | 0.85% | 55 |
|
|
2023
Q1 | $94.2M | Buy |
466,620
+14,180
| +3% | +$3.21M | 0.88% | 51 |
|
|
2022
Q4 | $98.6M | Sell |
452,440
-29,537
| -6% | -$6.45M | 0.99% | 40 |
|
|
2022
Q3 | $94.9M | Buy |
481,977
+20,222
| +4% | +$4.37M | 1.02% | 39 |
|
|
2022
Q2 | $98.8M | Buy |
461,755
+8,910
| +2% | +$2.18M | 0.95% | 43 |
|
|
2022
Q1 | $129M | Buy |
452,845
+19,355
| +4% | +$5.97M | 1.09% | 31 |
|
|
2021
Q4 | $163M | Sell |
433,490
-13,787
| -3% | -$5.36M | 1.24% | 21 |
|
|
2021
Q3 | $185M | Sell |
447,277
-22,741
| -5% | -$9.44M | 1.44% | 9 |
|
|
2021
Q2 | $174M | Sell |
470,018
-64,317
| -12% | -$21.5M | 1.45% | 9 |
|
|
2021
Q1 | $155M | Sell |
534,335
-61,615
| -10% | -$17.1M | 1.4% | 10 |
|
|
2020
Q4 | $149M | Sell |
595,950
-17,727
| -3% | -$4.22M | 1.4% | 13 |
|
|
2020
Q3 | $139M | Sell |
613,677
-16,909
| -3% | -$3.51M | 1.5% | 11 |
|
|
2020
Q2 | $110M | Sell |
630,586
-14,507
| -2% | -$2.32M | 1.31% | 18 |
|
|
2020
Q1 | $81.4M | Sell |
645,093
-37,399
| -5% | -$5.61M | 1.24% | 28 |
|
|
2019
Q4 | $104M | Sell |
682,492
-2,887
| -0.4% | -$400K | 1.27% | 19 |
|
|
2019
Q3 | $90.7M | Sell |
685,379
-17,486
| -2% | -$2.34M | 1.17% | 34 |
|
|
2019
Q2 | $99.7M | Sell |
702,865
-48,983
| -7% | -$6.64M | 1.27% | 19 |
|
|
2019
Q1 | $109M | Sell |
751,848
-16,686
| -2% | -$2.19M | 1.43% | 8 |
|
|
2018
Q4 | $87M | Sell |
768,534
-43,672
| -5% | -$5.47M | 1.31% | 18 |
|
|
2018
Q3 | $109M | Sell |
812,206
-15,235
| -2% | -$1.88M | 1.41% | 9 |
|
|
2018
Q2 | $92.9M | Sell |
827,441
-3,748
| -0.5% | -$405K | 1.28% | 18 |
|
|
2018
Q1 | $88.7M | Buy |
831,189
+59,910
| +8% | +$6.46M | 1.25% | 18 |
|
|
2017
Q4 | $84.4M | Buy |
771,279
+15,201
| +2% | +$1.65M | 1.23% | 24 |
|
|
2017
Q3 | $81.7M | Buy |
+756,078
| New | +$77.7M | 1.26% | 14 |
|
Other funds holding CRL
AI
Congress Asset Management's CRL Position: Q4 2025 in Review
Congress Asset Management sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 2,195 shares — an estimated $343K sold.
Congress Asset Management first reported a position in CRL in Q3 2017 and held it in 32 quarters. The position peaked at $185M in Q3 2021. 582 funds tracked by Wall St. Rank hold CRL as of Q4 2025.
- Congress Asset Management reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
- Congress Asset Management sold 2,195 Charles River Laboratories shares in Q4 2025, an estimated $343K.
- Congress Asset Management first reported a position in Charles River Laboratories in Q3 2017 and held it in 32 quarters.
- Congress Asset Management's Charles River Laboratories position peaked at $185M in Q3 2021.
- 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.
Based on Congress Asset Management's 13F filing for Q4 2025, filed 9 Jan 2026.